Cigna (CI) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Cigna (CI) reported $67.13 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 11%. EPS of $7.20 for the same period compares to $6.72 a year ago.The reported revenue represents a surprise of +7.09% over the Zacks Consensus Estimate of $62.69 billion. With the consensus EPS estimate being $7.14, the EPS surprise was +0.84%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Cigna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Medical Care Ratio - Cigna Healthcare: 83.2% versus 83.2% estimated by eight analysts on average.Medical Customers - Total: 18.05 million versus the four-analyst average estimate of 17.92 million.Medical Customers - U.S. Healthcare: 16.36 million versus 16.23 million estimated by four analysts on average.Covered Lives By Market Segment - Medical Customers - International Health: 1.69 million versus 1.69 million estimated by three analysts on average.Revenues- Net investment income: $236 million compared to the $219.84 million average estimate based on eight analysts. The reported number represents a change of -26.5% year over year.Revenues- Pharmacy: $53.65 billion versus the six-analyst average estimate of $49.16 billion. The reported number represents a year-over-year change of +19%.Revenues- Evernorth Health Services: $57.83 billion compared to the $54.43 billion average estimate based on five analysts. The reported number represents a change of +16.7% year over year.Revenues- Evernorth Health Services- Pharmacy: $53.99 billion compared to the $51.33 billion average estimate based on five analysts. The reported number represents a change of +16.9% year over year.Revenues- Cigna Healthcare- Premiums: $8.99 billion versus the five-analyst average estimate of $8.87 billion. The reported number represents a year-over-year change of -21.5%.Revenues- Premiums: $9.16 billion versus $8.7 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -20.1% change.Revenues- Fees and Other: $4.14 billion versus the five-analyst average estimate of $4.05 billion. The reported number represents a year-over-year change of +13.4%.Revenues- Cigna Healthcare: $10.8 billion versus $10.78 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -18.2% change.View all Key Company Metrics for Cigna here>>>Shares of Cigna have returned -7% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.One Big Gain, Every Trading DayTo help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cigna Group (CI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks